Vardenafil Tablet, Orally Disintegrating
Product Images NDC 46708-235

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Vardenafil (NDC 46708-235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

4 Tablets (Vardenafil 25mg)

Packaging label for Vardenafil Hydrochloride Orally Disintegrating Tablets, 10 mg strength, with 4 tablets per package. The label shows the product name, dosage form, strength, NDC number 46708-235-04, and instructions indicating the tablet should be placed on the tongue and taken without liquid. The labeler is Alembic Pharmaceuticals Limited.*

FDA Label Image

Figure 1 (Vardenafil Fig1)

Three line graphs showing mean maximal changes in systolic blood pressure, diastolic blood pressure, and heart rate over time relative to timing of vardenafil treatment before NTG administration. The x-axis represents time points (24h, 8h, 4h, 1h) before treatment, with y-axes showing changes in mmHg for blood pressures and bpm for heart rate, including error bars.*

FDA Label Image

Figure 2 (Vardenafil Fig2)

A line graph depicting mean change in mmHg over time in hours for placebo and Vardenafil 5 mg under simultaneous and 6-hour separation conditions. The x-axis represents time (0 to 6 hours), and the y-axis shows mean blood pressure change, ranging approximately from -15 to 15 mmHg, with four trend lines for each condition.*

FDA Label Image

Figure 3 (Vardenafil Fig3)

A line graph showing mean change in mmHg over 6 hours comparing placebo and vardenafil 5 mg effects under simultaneous and 6-hour separation conditions, with distinct markers for each group and time on the x-axis.*

FDA Label Image

Figure 4 (Vardenafil Fig4)

A line graph depicting the mean change in mmHg over time (hours) for placebo and Vardenafil at 10 mg and 20 mg doses. The graph includes data for two placebo stages and shows that both Vardenafil doses generally result in a greater decrease in mmHg compared to placebo over a six-hour period.*

FDA Label Image

Figure 5 (Vardenafil Fig5)

A line graph depicting the mean change in blood pressure (mmHg) over a 6-hour period comparing placebo at two stages with Vardenafil 5 mg and 10 mg doses. The x-axis represents time in hours, and the y-axis shows mean change in blood pressure.*

FDA Label Image

Figure 6 (Vardenafil Fig6)

A line graph illustrating the mean change in mmHg over 6 hours for Terazosin with various treatments: placebo, 10 mg vardenafil, and 20 mg vardenafil, each administered either with 6-hour separation or simultaneously. The x-axis represents time in hours, and the y-axis shows mean change in mmHg.*

FDA Label Image

Figure 7 (Vardenafil Fig7)

A line graph titled 'TAMSULOSIN' showing mean change in mmHg over time in hours (0 to 6). It compares placebo, 10 mg, and 20 mg doses of Vardenafil under conditions of 6-hour separation and simultaneous administration. Each condition is represented by distinct line styles and markers, showing blood pressure changes over the 6-hour period.*

FDA Label Image

Figure 8 (Vardenafil Fig8)

A line graph depicting plasma concentration (µg/L) of Vardenafil over time (hours). The solid line shows the mean plasma concentration peaking early and gradually declining over 15 hours, with vertical error bars indicating variability at each time point.*

FDA Label Image

Structure (Vardenafil Str)

Chemical structure of Vardenafil hydrochloride trihydrate depicted as a two-dimensional molecular diagram showing atomic connectivity and bonds.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.